NewsBenzingaHC Wainwright & Co. 重申对 Sarepta Therapeutics 的“卖出”评级，维持 5 美元目标价 HC Wainwright & Co. 重申对 Sarepta Therapeutics 的“卖出”评级，维持 5 美元目标价 Benzinga 2026.10.05 11:54 (GMT+0) Open on Benzinga Other news Wells Fargo Maintains Equal-Weight on PENN Entertainment, Lowers Price Target to $22 HC Wainwright & Co. Reiterates Buy on Rigel Pharmaceuticals, Maintains $85 Price Target Alphabet Stock Rises: What's Going On? $1000 Invested In Agilent Technologies 10 Years Ago Would Be Worth This Much Today Wells Fargo Maintains Equal-Weight on MGM Resorts International, Lowers Price Target to $29 Why Is Applied Digital Stock Surging on Monday?
